Last reviewed · How we verify
Purdue Pharma, Canada — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| PRC-063 oral capsules | PRC-063 oral capsules | phase 3 | Serotonin-norepinephrine reuptake inhibitor (SNRI) | Pain, Depression |
Therapeutic area mix
- Pain, Depression · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams University · 1 shared drug class
- Eli Lilly and Company · 1 shared drug class
- Jefferson Clinic, P.C. · 1 shared drug class
- Ministry of Health & Welfare, Korea · 1 shared drug class
- National Institute of Mental Health (NIMH) · 1 shared drug class
- New York State Psychiatric Institute · 1 shared drug class
- North Dakota State University · 1 shared drug class
- Pfizer · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Purdue Pharma, Canada:
- Purdue Pharma, Canada pipeline updates — RSS
- Purdue Pharma, Canada pipeline updates — Atom
- Purdue Pharma, Canada pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Purdue Pharma, Canada — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/purdue-pharma-canada. Accessed 2026-05-14.